Gripovac 3

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

inaktivirano gripa-virus, prašičev

Available from:

Merial S.A.S. 

ATC code:

QI09AA03

INN (International Name):

inactivated influenza-A virus, swine

Therapeutic group:

Prašiči

Therapeutic area:

Imunologija

Therapeutic indications:

Aktivno imunizacijo prašičev v starosti od 56 dni naprej, vključno z noseča svinje proti prašičji gripi, ki jih povzročajo podtipov H1N1, H3N2 in H1N2 za zmanjšanje kliničnih znakov in virusnih pljuč obremenitev po okužbi. Začetek imunosti: 7 dni po primarnem cepljenju. Trajanje imunosti: 4 mesecih, v štrucah, cepljenih med starost 56 in 96 dni do 6 mesecev, v štrucah, cepljenih prvič na 96 dni in več. Aktivna imunizacija nosečih svinj po končani primarni imunizaciji z dajanjem enega samega odmerka 14 dni pred prasitvijo razviti visoko kolostralno imunost, ki zagotavlja klinično zaščito pujskov vsaj 33 dni po rojstvu.

Product summary:

Revision: 1

Authorization status:

Umaknjeno

Authorization date:

2010-01-14

Patient Information leaflet

                                Zdravilo nima veā dovoljenja za promet
15
B. NAVODILO ZA UPORABO
Zdravilo nima veā dovoljenja za promet
16
NAVODILO ZA UPORABO ZA:
GRIPOVAC 3
Suspenzija za injiciranje za prašiče
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
MERIAL
29 avenue Tony Garnier
69007 Lyon,
Francija
Izdelovalec, odgovoren za sproščanje serij:
IDT Biologika GmbH
Am Pharmapark
06861 Dessau-Rosslau
Nemčija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Gripovac 3 suspenzija za injiciranje za prašiče
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN
Bistra rumeno-oranžna do rožnato obarvana suspenzija za injiciranje.
Vsak odmerek (2ml) vsebuje:
ZDRAVILNE UČINKOVINE:
Sevi inaktiviranega virusa Influenca A /prašiči/
Bakum/IDT1769/2003 (H3N2)
≥ 10.53 log
2
GMNU
1
Haselünne/IDT2617/2003 (H1N1)
≥ 10.22 log
2
GMNU
1
Bakum/1832/2000 (H1N2)
≥ 12.34 log2 GMNU
1
1
GMNU = Geometrijska sredina neutralizirajočih enot induciranih pri
budrah po dvakratnem
imuniziranju s po 0,5 ml tega cepiva
DODATEK:
Karbomer 971 P NF
2.0 mg
POMOŽNA SNOV:
Tiomersal
0,21 mg
4.
INDIKACIJA(E)
Aktivna imunizacija prašičev od 56 dneva starosti naprej, vključno
z brejimi svinjami, proti influenci
prašičev, ki jo povzročajo podtipi H1N1, H3N2 in H1N2, za
zmanjšanje kliničnih znakov in
prisotnosti virusa v pljučih po okužbi.
Nastop imunosti:
7 dni po primarnem cepljenju
Zdravilo nima veā dovoljenja za promet
17
Trajanje imunosti:
4 mesece pri prašičih cepljenih v starosti med 56 in 96 dni
6 mesecev pri prašičih, ki so bili prvič cepljeni po 96 dneh
starosti
Aktivna imunizacija brejih svinj po zaključeni primarni imunizaciji z
dajanjem enega odmerka 14
dni pred prasitvijo, za doseganje visoke kolostralne imunosti, ki
pujske ščiti vsaj 33 dni po rojstvu.
5.
KONTRAINDIKACIJE
Jih ni.
6.
NEŽELENI UČINKI
Na mestu injiciranja se lahko v zelo redkih primerih pojavi manjša
pr
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Zdravilo nima veā dovoljenja za promet
1
DODATEK I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-09-2018
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-09-2018
Public Assessment Report Public Assessment Report Bulgarian 04-09-2018
Patient Information leaflet Patient Information leaflet Spanish 04-09-2018
Public Assessment Report Public Assessment Report Spanish 04-09-2018
Patient Information leaflet Patient Information leaflet Czech 04-09-2018
Public Assessment Report Public Assessment Report Czech 04-09-2018
Patient Information leaflet Patient Information leaflet Danish 04-09-2018
Public Assessment Report Public Assessment Report Danish 04-09-2018
Patient Information leaflet Patient Information leaflet German 04-09-2018
Public Assessment Report Public Assessment Report German 04-09-2018
Patient Information leaflet Patient Information leaflet Estonian 04-09-2018
Public Assessment Report Public Assessment Report Estonian 04-09-2018
Patient Information leaflet Patient Information leaflet Greek 04-09-2018
Public Assessment Report Public Assessment Report Greek 04-09-2018
Patient Information leaflet Patient Information leaflet English 04-09-2018
Public Assessment Report Public Assessment Report English 04-09-2018
Patient Information leaflet Patient Information leaflet French 04-09-2018
Public Assessment Report Public Assessment Report French 04-09-2018
Patient Information leaflet Patient Information leaflet Italian 04-09-2018
Public Assessment Report Public Assessment Report Italian 04-09-2018
Patient Information leaflet Patient Information leaflet Latvian 04-09-2018
Public Assessment Report Public Assessment Report Latvian 04-09-2018
Patient Information leaflet Patient Information leaflet Lithuanian 04-09-2018
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-09-2018
Public Assessment Report Public Assessment Report Lithuanian 04-09-2018
Patient Information leaflet Patient Information leaflet Hungarian 04-09-2018
Summary of Product characteristics Summary of Product characteristics Hungarian 04-09-2018
Public Assessment Report Public Assessment Report Hungarian 04-09-2018
Patient Information leaflet Patient Information leaflet Maltese 04-09-2018
Public Assessment Report Public Assessment Report Maltese 04-09-2018
Patient Information leaflet Patient Information leaflet Dutch 04-09-2018
Public Assessment Report Public Assessment Report Dutch 04-09-2018
Patient Information leaflet Patient Information leaflet Polish 04-09-2018
Public Assessment Report Public Assessment Report Polish 04-09-2018
Patient Information leaflet Patient Information leaflet Portuguese 04-09-2018
Summary of Product characteristics Summary of Product characteristics Portuguese 04-09-2018
Public Assessment Report Public Assessment Report Portuguese 04-09-2018
Patient Information leaflet Patient Information leaflet Romanian 04-09-2018
Public Assessment Report Public Assessment Report Romanian 04-09-2018
Patient Information leaflet Patient Information leaflet Slovak 04-09-2018
Public Assessment Report Public Assessment Report Slovak 04-09-2018
Patient Information leaflet Patient Information leaflet Finnish 04-09-2018
Public Assessment Report Public Assessment Report Finnish 04-09-2018
Patient Information leaflet Patient Information leaflet Swedish 04-09-2018
Public Assessment Report Public Assessment Report Swedish 04-09-2018
Patient Information leaflet Patient Information leaflet Norwegian 04-09-2018
Summary of Product characteristics Summary of Product characteristics Norwegian 04-09-2018
Patient Information leaflet Patient Information leaflet Icelandic 04-09-2018
Summary of Product characteristics Summary of Product characteristics Icelandic 04-09-2018
Patient Information leaflet Patient Information leaflet Croatian 04-09-2018

View documents history